MedTrace Logo

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00008216 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2014-06-06

No results posted yet for this study

Summary

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.

Conditions

  • Adult Langerhans Cell Histiocytosis
  • Childhood Langerhans Cell Histiocytosis
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms

Interventions

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Sponsors & Collaborators

Principal Investigators

  • David G. Savage, MD · Herbert Irving Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-07-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00008216 on ClinicalTrials.gov